South Korea · Delayed Price · Currency is KRW Genomictree Statistics
Total Valuation
Genomictree has a market cap or net worth of KRW 276.90 billion. The enterprise value is 198.06 billion.
| Market Cap | 276.90B |
| Enterprise Value | 198.06B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Genomictree has 24.53 million shares outstanding. The number of shares has increased by 1.13% in one year.
| Current Share Class | 24.53M |
| Shares Outstanding | 24.53M |
| Shares Change (YoY) | +1.13% |
| Shares Change (QoQ) | -3.74% |
| Owned by Insiders (%) | 15.68% |
| Owned by Institutions (%) | 0.16% |
| Float | 20.68M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 93.98 |
| PB Ratio | 2.27 |
| P/TBV Ratio | 2.30 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 67.22 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 60.85, with a Debt / Equity ratio of 0.00.
| Current Ratio | 60.85 |
| Quick Ratio | 60.18 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.00 |
| Interest Coverage | -47.03 |
Financial Efficiency
Return on equity (ROE) is -7.69% and return on invested capital (ROIC) is -25.82%.
| Return on Equity (ROE) | -7.69% |
| Return on Assets (ROA) | -5.92% |
| Return on Invested Capital (ROIC) | -25.82% |
| Return on Capital Employed (ROCE) | -9.54% |
| Weighted Average Cost of Capital (WACC) | 4.86% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.02 |
| Inventory Turnover | 9.05 |
Taxes
In the past 12 months, Genomictree has paid 12.65 million in taxes.
| Income Tax | 12.65M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -41.95% in the last 52 weeks. The beta is 0.10, so Genomictree's price volatility has been lower than the market average.
| Beta (5Y) | 0.10 |
| 52-Week Price Change | -41.95% |
| 50-Day Moving Average | 11,871.60 |
| 200-Day Moving Average | 18,597.05 |
| Relative Strength Index (RSI) | 42.39 |
| Average Volume (20 Days) | 92,966 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Genomictree had revenue of KRW 2.95 billion and -9.03 billion in losses. Loss per share was -373.16.
| Revenue | 2.95B |
| Gross Profit | -164.40M |
| Operating Income | -11.74B |
| Pretax Income | -9.18B |
| Net Income | -9.03B |
| EBITDA | -10.55B |
| EBIT | -11.74B |
| Loss Per Share | -373.16 |
Balance Sheet
The company has 79.18 billion in cash and 43.98 million in debt, with a net cash position of 79.14 billion or 3,226.58 per share.
| Cash & Cash Equivalents | 79.18B |
| Total Debt | 43.98M |
| Net Cash | 79.14B |
| Net Cash Per Share | 3,226.58 |
| Equity (Book Value) | 121.93B |
| Book Value Per Share | 5,083.76 |
| Working Capital | 79.83B |
Cash Flow
In the last 12 months, operating cash flow was -10.55 billion and capital expenditures -1.86 billion, giving a free cash flow of -12.41 billion.
| Operating Cash Flow | -10.55B |
| Capital Expenditures | -1.86B |
| Depreciation & Amortization | 1.19B |
| Net Borrowing | -56.21M |
| Free Cash Flow | -12.41B |
| FCF Per Share | -505.87 |
Margins
| Gross Margin | -5.58% |
| Operating Margin | -398.40% |
| Pretax Margin | -311.63% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Genomictree does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.13% |
| Shareholder Yield | -1.13% |
| Earnings Yield | -3.26% |
| FCF Yield | -4.48% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 14, 2018. It was a forward split with a ratio of 2.
| Last Split Date | Sep 14, 2018 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Genomictree has an Altman Z-Score of 115.28 and a Piotroski F-Score of 1.
| Altman Z-Score | 115.28 |
| Piotroski F-Score | 1 |